T. Shanmugalingam, A. Soultati, S. Chowdhury, S. Rudman i inni. Global incidence and outcome of testicular cancer. „Clin Epidemiol”. 5, s. 417–427, 2013. DOI: 10.2147/CLEP.S34430. PMID: 24204171.
C. La Vecchia, C. Bosetti, F. Lucchini, P. Bertuccio i inni. Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. „Ann Oncol”. 21 (6), s. 1323–1360, 2010. DOI: 10.1093/annonc/mdp530. PMID: 19948741.
K.A. McGlynn, B. Trabert. Adolescent and adult risk factors for testicular cancer. „Nat Rev Urol”. 9 (6), s. 339–349, 2012. DOI: 10.1038/nrurol.2012.61. PMID: 22508459.
B. Trabert, J. Chen, S.S. Devesa, F. Bray i inni. International patterns and trends in testicular cancer incidence, overall and by histologic subtype, 1973-2007. „Andrology”. 3 (1), s. 4–12, 2015. DOI: 10.1111/andr.293. PMID: 25331326.
M.J. Garner, M.C. Turner, P. Ghadirian, D. Krewski. Epidemiology of testicular cancer: an overview. „Int J Cancer”. 116 (3), s. 331–339, 2005. DOI: 10.1002/ijc.21032. PMID: 15818625.
S.M. Stevenson, W.T. Lowrance. Epidemiology and Diagnosis of Testis Cancer. „Urol Clin North Am”. 42 (3), s. 269–275, 2015. DOI: 10.1016/j.ucl.2015.04.001. PMID: 26216814.
A. Pettersson, L. Richiardi, A. Nordenskjold, M. Kaijser i inni. Age at surgery for undescended testis and risk of testicular cancer. „N Engl J Med”. 356 (18), s. 1835–1841, 2007. DOI: 10.1056/NEJMoa067588. PMID: 17476009.
C. Myrup, T.H. Schnack, J. Wohlfahrt. Correction of cryptorchidism and testicular cancer. „N Engl J Med”. 357 (8), s. 825–827, 2007. DOI: 10.1056/NEJMc071510. PMID: 17715418.
K.P. Dieckmann, U. Pichlmeier. Clinical epidemiology of testicular germ cell tumors. „World J Urol”. 22 (1), s. 2–14, 2004. DOI: 10.1007/s00345-004-0398-8. PMID: 15034740.
S.D. Fosså, J. Chen, S.J. Schonfeld, K.A. McGlynn i inni. Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men. „J Natl Cancer Inst”. 97 (14), s. 1056–1066, 2005. DOI: 10.1093/jnci/dji185. PMID: 16030303.
K.P. Dieckmann, V. Loy. Prevalence of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasms. „J Clin Oncol”. 14 (12), s. 3126–3132, 1996. DOI: 10.1200/JCO.1996.14.12.3126. PMID: 8955658.
K. Hemminki, X. Li. Familial risk in testicular cancer as a clue to a heritable and environmental aetiology. „Br J Cancer”. 90 (9), s. 1765–1770, 2004. DOI: 10.1038/sj.bjc.6601714. PMID: 15208620.
K. Hemminki, X. Li. Cancer risks in twins: results from the Swedish family-cancer database. „Int J Cancer”. 99 (6), s. 873–878, Jun 2002. DOI: 10.1002/ijc.10441. PMID: 12115491.
V.P. Doria-Rose, M.L. Biggs, N.S. Weiss. Subfertility and the risk of testicular germ cell tumors (United States). „Cancer Causes Control”. 16 (6), s. 651–656, 2005. DOI: 10.1007/s10552-005-0169-x. PMID: 16049803.
J.D. Raman, C.F. Nobert, M. Goldstein. Increased incidence of testicular cancer in men presenting with infertility and abnormal semen analysis. „J Urol”. 174 (5), s. 1819–1822, Nov 2005. DOI: 10.1097/01.ju.0000177491.98461.aa. PMID: 16217294.
M. Mancini, L. Carmignani, G. Gazzano, P. Sagone i inni. High prevalence of testicular cancer in azoospermic men without spermatogenesis. „Hum Reprod”. 22 (4), s. 1042–1046, 2007. DOI: 10.1093/humrep/del500. PMID: 17220165.
M. Kathrins, T.F. Kolon. Malignancy in disorders of sex development. „Transl Androl Urol”. 5 (5), s. 794–798, 2016. DOI: 10.21037/tau.2016.08.09. PMID: 27785439.
R. Hersmus, H. Stoop, S.J. White, S.L. Drop i inni. Delayed Recognition of Disorders of Sex Development (DSD): A Missed Opportunity for Early Diagnosis of Malignant Germ Cell Tumors. „Int J Endocrinol”. 2012, 2012. DOI: 10.1155/2012/671209. PMID: 22315593.
J. Pleskacova, R. Hersmus, J.W. Oosterhuis, B.A. Setyawati i inni. Tumor risk in disorders of sex development. „Sex Dev”. 4 (4–5), s. 259–269, Sep 2010. DOI: 10.1159/000314536. PMID: 20558977.
L.H. Looijenga, R. Hersmus, J.W. Oosterhuis, M. Cools i inni. Tumor risk in disorders of sex development (DSD). „Best Pract Res Clin Endocrinol Metab”. 21 (3), s. 480–495, 2007. DOI: 10.1016/j.beem.2007.05.001. PMID: 17875493.
G. Accardo, G. Vallone, D. Esposito, F. Barbato i inni. Testicular parenchymal abnormalities in Klinefelter syndrome: a question of cancer? Examination of 40 consecutive patients. „Asian J Androl”. 17 (1). s. 154–158. DOI: 10.4103/1008-682X.128514. PMID: 25130577.
H.T. Heller, M.C. Oliff, P.M. Doubilet, M.P. O’Leary i inni. Testicular microlithiasis: prevalence and association with primary testicular neoplasm. „J Clin Ultrasound”. 42 (7), s. 423–426, 2014. DOI: 10.1002/jcu.22144. PMID: 24585495.
M.L. Cooper, M. Kaefer, R. Fan, R.C. Rink i inni. Testicular microlithiasis in children and associated testicular cancer. „Radiology”. 270 (3), s. 857–863, 2014. DOI: 10.1148/radiol.13130394. PMID: 24475810.
B.J. DeCastro, A.C. Peterson, R.A. Costabile. A 5-year followup study of asymptomatic men with testicular microlithiasis. „J Urol”. 179 (4), s. 1420–1423, 2008. DOI: 10.1016/j.juro.2007.11.080. PMID: 18289592.
K. Patja, E. Pukkala, R. Sund, M. Iivanainen i inni. Cancer incidence of persons with Down syndrome in Finland: a population-based study. „Int J Cancer”. 118 (7), s. 1769–1772, 2006. DOI: 10.1002/ijc.21518. PMID: 16231334.
H. Hasle, J.M. Friedman, J.H. Olsen, S.A. Rasmussen. Low risk of solid tumors in persons with Down syndrome. „Genet Med”. 18 (11), s. 1151–1157, 2016. DOI: 10.1038/gim.2016.23. PMID: 27031084.
J.J. Goedert, M.P. Purdue, T.S. McNeel, K.A. McGlynn i inni. Risk of germ cell tumors among men with HIV/acquired immunodeficiency syndrome. „Cancer Epidemiol Biomarkers Prev”. 16 (6), s. 1266–1269, 2007. DOI: 10.1158/1055-9965.EPI-07-0042. PMID: 17548695.
K. Lin, R. Sharangpani. Screening for testicular cancer: an evidence review for the U.S. Preventive Services Task Force. „Ann Intern Med”. 153 (6), s. 396–399, 2010. DOI: 10.7326/0003-4819-153-6-201009210-00007. PMID: 20855803.
S.F. Oosting, E.C. de Haas, T.P. Links, D. de Bruin i inni. Prevalence of paraneoplastic hyperthyroidism in patients with metastatic non-seminomatous germ-cell tumors. „Ann Oncol”. 21 (1), s. 104–108, 2010. DOI: 10.1093/annonc/mdp265. PMID: 19605510.
J.E. Elzinga-Tinke, G.R. Dohle, L.H. Looijenga. Etiology and early pathogenesis of malignant testicular germ cell tumors: towards possibilities for preinvasive diagnosis. „Asian J Androl”. 17 (3). s. 381–393. DOI: 10.4103/1008-682X.148079. PMID: 25791729.
B. Boldajipour, E. Raz. What is left behind--quality control in germ cell migration. „Sci STKE”. 2007 (383), 2007. DOI: 10.1126/stke.3832007pe16. PMID: 17456805.
E.A. Rapley, C. Turnbull, A.A. Al Olama, E.T. Dermitzakis i inni. A genome-wide association study of testicular germ cell tumor. „Nat Genet”. 41 (7), s. 807–810, 2009. DOI: 10.1038/ng.394. PMID: 19483681.
P.A. Kanetsky, N. Mitra, S. Vardhanabhuti, M. Li i inni. Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. „Nat Genet”. 41 (7), s. 811–815, 2009. DOI: 10.1038/ng.393. PMID: 19483682.
A. McIntyre, B. Summersgill, B. Grygalewicz, A.J. Gillis i inni. Amplification and overexpression of the KIT gene is associated with progression in the seminoma subtype of testicular germ cell tumors of adolescents and adults. „Cancer Res”. 65 (18), s. 8085–8089, 2005. DOI: 10.1158/0008-5472.CAN-05-0471. PMID: 16166280.
M. Studniarek, K. Skrobisz-Balandowska, E. Modzelewska. Scrotal imaging. „J Ultrason”. 15 (62), s. 245–258, 2015. DOI: 10.15557/JoU.2015.0021. PMID: 26674847.
G.W. Barrisford, E.I. Kreydin, M.A. Preston, D. Rodriguez i inni. Role of imaging in testicular cancer: current and future practice. „Future Oncol”. 11 (18), s. 2575–2586, 2015. DOI: 10.2217/fon.15.194. PMID: 26314944.
S. Hilton, H.W. Herr, J.B. Teitcher, C.B. Begg i inni. CT detection of retroperitoneal lymph node metastases in patients with clinical stage I testicular nonseminomatous germ cell cancer: assessment of size and distribution criteria. „AJR Am J Roentgenol”. 169 (2), s. 521–525, 1997. DOI: 10.2214/ajr.169.2.9242768. PMID: 9242768.
E.I. Kreydin, G.W. Barrisford, A.S. Feldman, M.A. Preston. Testicular cancer: what the radiologist needs to know. „AJR Am J Roentgenol”. 200 (6), s. 1215–1225, 2013. DOI: 10.2214/AJR.12.10319. PMID: 23701056.
S.A. Sohaib, D.M. Koh, Y. Barbachano, J. Parikh i inni. Prospective assessment of MRI for imaging retroperitoneal metastases from testicular germ cell tumours. „Clin Radiol”. 64 (4), s. 362–367, 2009. DOI: 10.1016/j.crad.2008.10.011. PMID: 19264179.
M. de Wit, W. Brenner, M. Hartmann, J. Kotzerke i inni. [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial. „Ann Oncol”. 19 (9), s. 1619–1623, 2008. DOI: 10.1093/annonc/mdn170. PMID: 18453520.
R.A. Huddart, M.J. O’Doherty, A. Padhani, G.J. Rustin i inni. 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group. „J Clin Oncol”. 25 (21), s. 3090–3095, 2007. DOI: 10.1200/JCO.2006.09.3831. PMID: 17634488.
M. De Santis, A. Becherer, C. Bokemeyer, F. Stoiber i inni. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. „J Clin Oncol”. 22 (6), s. 1034–1039, 2004. DOI: 10.1200/JCO.2004.07.188. PMID: 15020605.
C. Winter, P. Albers. Testicular germ cell tumors: pathogenesis, diagnosis and treatment. „Nat Rev Endocrinol”. 7 (1), s. 43–53, 2011. DOI: 10.1038/nrendo.2010.196. PMID: 21116298.
M.C. Mir, N. Pavan, M.L. Gonzalgo. Current Clinical Applications of Testicular Cancer Biomarkers. „Urol Clin North Am”. 43 (1), s. 119–125, 2016. DOI: 10.1016/j.ucl.2015.08.011. PMID: 26614034.
J.C. Milose, C.P. Filson, A.Z. Weizer, K.S. Hafez i inni. Role of biochemical markers in testicular cancer: diagnosis, staging, and surveillance. „Open Access J Urol”. 4, s. 1–8, 2011. DOI: 10.2147/OAJU.S15063. PMID: 24198649.
S.M. Pearce, S.L. Liauw, S.E. Eggener. Management of Low-Stage Testicular Seminoma. „Urol Clin North Am”. 42 (3), s. 287–298, 2015. DOI: 10.1016/j.ucl.2015.04.003. PMID: 26216816.
M. Chovanec, N. Hanna, K.C. Cary, L. Einhorn i inni. Management of stage I testicular germ cell tumours. „Nat Rev Urol”. 13 (11), s. 663–673, 2016. DOI: 10.1038/nrurol.2016.164. PMID: 27618772.
E. Rajpert-De Meyts, K.A. McGlynn, K. Okamoto, M.A. Jewett i inni. Testicular germ cell tumours. „Lancet”. 387 (10029), s. 1762–1774, 2016. DOI: 10.1016/S0140-6736(15)00991-5. PMID: 26651223.
R.J. Groll, P. Warde, M.A. Jewett. A comprehensive systematic review of testicular germ cell tumor surveillance. „Crit Rev Oncol Hematol”. 64 (3), s. 182–197, 2007. DOI: 10.1016/j.critrevonc.2007.04.014. PMID: 17644403.
P. Warde, L. Specht, A. Horwich, T. Oliver i inni. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. „J Clin Oncol”. 20 (22), s. 4448–4452, 2002. DOI: 10.1200/JCO.2002.01.038. PMID: 12431967.
J. Aparicio, P. Maroto, X. García del Muro, A. Sánchez-Muñoz i inni. Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG). „Ann Oncol”. 25 (11), s. 2173–2178, 2014. DOI: 10.1093/annonc/mdu437. PMID: 25210015.
T. Tandstad, O. Ståhl, O. Dahl, H.S. Haugnes i inni. Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA). „Ann Oncol”. 27 (7), s. 1299–1304, 2016. DOI: 10.1093/annonc/mdw164. PMID: 27052649.
P. Chung, G. Daugaard, S. Tyldesley, E.G. Atenafu i inni. Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance. „Cancer Med”. 4 (1), s. 155–160, 2015. DOI: 10.1002/cam4.324. PMID: 25236854.
P. Chung, P. Warde. Stage I seminoma: adjuvant treatment is effective but is it necessary?. „J Natl Cancer Inst”. 103 (3), s. 194–196, 2011. DOI: 10.1093/jnci/djq535. PMID: 21212383.
T. Tandstad, R. Smaaland, A. Solberg, R.M. Bremnes i inni. Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group. „J Clin Oncol”. 29 (6), s. 719–725, 2011. DOI: 10.1200/JCO.2010.30.1044. PMID: 21205748.
R.T. Oliver, G.M. Mead, G.J. Rustin, J.K. Joffe i inni. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). „J Clin Oncol”. 29 (8), s. 957–962, 2011. DOI: 10.1200/JCO.2009.26.4655. PMID: 21282539.
R.T. Oliver, M.D. Mason, G.M. Mead, H. von der Maase i inni. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. „Lancet”. 366 (9482). s. 293–300. DOI: 10.1016/S0140-6736(05)66984-X. PMID: 16039331.
J. Aparicio, J.R. Germà, X. García del Muro, P. Maroto i inni. Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. „J Clin Oncol”. 23 (34), s. 8717–8723, 2005. DOI: 10.1200/JCO.2005.01.9810. PMID: 16260698.
J. Aparicio, P. Maroto, X.G. del Muro, J. Gumà i inni. Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study. „J Clin Oncol”. 29 (35), s. 4677–4681, 2011. DOI: 10.1200/JCO.2011.36.0503. PMID: 22042940.
W.G. Jones, S.D. Fossa, G.M. Mead, J.T. Roberts i inni. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). „J Clin Oncol”. 23 (6), s. 1200–1208, 2005. DOI: 10.1200/JCO.2005.08.003. PMID: 15718317.
S.D. Fosså, A. Horwich, J.M. Russell, J.T. Roberts i inni. Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. „J Clin Oncol”. 17 (4), s. 1146, 1999. DOI: 10.1200/JCO.1999.17.4.1146. PMID: 10561173.
N. Boujelbene, A. Cosinschi, N. Boujelbene, K. Khanfir i inni. Pure seminoma: a review and update. „Radiat Oncol”. 6, s. 90, 2011. DOI: 10.1186/1748-717X-6-90. PMID: 21819630.
P.W. Chung, M.K. Gospodarowicz, T. Panzarella, M.A. Jewett i inni. Stage II testicular seminoma: patterns of recurrence and outcome of treatment. „Eur Urol”. 45 (6), s. 754–759, 2004. DOI: 10.1016/j.eururo.2004.01.020. PMID: 15149748.
J. Classen, H. Schmidberger, C. Meisner, R. Souchon i inni. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. „J Clin Oncol”. 21 (6), s. 1101–1106, 2003. DOI: 10.1200/JCO.2003.06.065. PMID: 12637477.
J. Domont, C. Massard, A. Patrikidou, A. Bossi i inni. A risk-adapted strategy of radiotherapy or cisplatin-based chemotherapy in stage II seminoma. „Urol Oncol”. 31 (5), s. 697–705, 2013. DOI: 10.1016/j.urolonc.2011.04.004. PMID: 21665493.
X. Garcia-del-Muro, P. Maroto, J. Gumà, J. Sastre i inni. Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study. „J Clin Oncol”. 26 (33), s. 5416–5421, 2008. DOI: 10.1200/JCO.2007.15.9103. PMID: 18936476.
S. Krege, C. Boergermann, R. Baschek, A. Hinke i inni. Single agent carboplatin for CS IIA/B testicular seminoma. A phase II study of the German Testicular Cancer Study Group (GTCSG). „Ann Oncol”. 17 (2), s. 276–280, 2006. DOI: 10.1093/annonc/mdj039. PMID: 16254023.
S. Hinz, M. Schrader, C. Kempkensteffen, R. Bares i inni. The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma. „J Urol”. 179 (3), s. 936–940, 2008. DOI: 10.1016/j.juro.2007.10.054. PMID: 18207171.
A. Becherer, M. De Santis, G. Karanikas, M. Szabó i inni. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals. „Eur J Radiol”. 54 (2), s. 284–288, 2005. DOI: 10.1016/j.ejrad.2004.07.012. PMID: 15837411.
Y. Ehrlich, M.J. Brames, S.D. Beck, R.S. Foster i inni. Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission?. „J Clin Oncol”. 28 (4), s. 531–536, 2010. DOI: 10.1200/JCO.2009.23.0714. PMID: 20026808.
G. Read, S.P. Stenning, M.H. Cullen, M.C. Parkinson i inni. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. „J Clin Oncol”. 10 (11), s. 1762–1768, 1992. DOI: 10.1200/JCO.1992.10.11.1762. PMID: 1403057.
J.F. Sturgeon, M.J. Moore, D.M. Kakiashvili, I. Duran i inni. Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital’s experience. „Eur Urol”. 59 (4), s. 556–562, 2011. DOI: 10.1016/j.eururo.2010.12.010. PMID: 21190791.
C. Kollmannsberger, C. Moore, K.N. Chi, N. Murray i inni. Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy. „Ann Oncol”. 21 (6), s. 1296–1301, 2010. DOI: 10.1093/annonc/mdp473. PMID: 19875756.
M.H. Cullen, S.P. Stenning, M.C. Parkinson, S.D. Fossa i inni. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. „J Clin Oncol”. 14 (4), s. 1106–1113, 1996. DOI: 10.1200/JCO.1996.14.4.1106. PMID: 8648364.
J. Pont, W. Albrecht, G. Postner, F. Sellner i inni. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. „J Clin Oncol”. 14 (2), s. 441–448, 1996. DOI: 10.1200/JCO.1996.14.2.441. PMID: 8636755.
C. Chevreau, C. Mazerolles, M. Soulié, M.H. Gaspard i inni. Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion. „Eur Urol”. 46 (2), s. 209–214, 2004. DOI: 10.1016/j.eururo.2004.03.022. PMID: 15245815.
R.T. Oliver, J. Ong, J. Shamash, R. Ravi i inni. Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with Stage 1 nonseminoma treated with adjuvant chemotherapy. „Urology”. 63 (3), s. 556–561, 2004. DOI: 10.1016/j.urology.2003.10.023. PMID: 15028457.
T. Tandstad, O. Ståhl, U. Håkansson, O. Dahl i inni. One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group. „Ann Oncol”. 25 (11), s. 2167–2172, 2014. DOI: 10.1093/annonc/mdu375. PMID: 25114021.
P. Albers, R. Siener, S. Krege, H.U. Schmelz i inni. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. „J Clin Oncol”. 26 (18), s. 2966–2972, 2008. DOI: 10.1200/JCO.2007.12.0899. PMID: 18458040.
C.J. Sweeney, B.P. Hermans, D.K. Heilman, R.S. Foster i inni. Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma-predominant testis cancer. „J Clin Oncol”. 18 (2), s. 358–362, 2000. DOI: 10.1200/JCO.2000.18.2.358. PMID: 10637250.
A. Heidenreich, P. Albers, M. Hartmann, S. Kliesch i inni. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. „J Urol”. 169 (5), s. 1710–1714, 2003. DOI: 10.1097/01.ju.0000060960.18092.54. PMID: 12686815.
A. Heidenreich, D. Pfister. Retroperitoneal lymphadenectomy and resection for testicular cancer: an update on best practice. „Ther Adv Urol”. 4 (4), s. 187–205, 2012. DOI: 10.1177/1756287212443170. PMID: 22852029.
S.D. Beck, A.L. Bey, R. Bihrle, R.S. Foster. Ejaculatory status and fertility rates after primary retroperitoneal lymph node dissection. „J Urol”. 184 (5), s. 2078–2080, Nov 2010. DOI: 10.1016/j.juro.2010.06.146. PMID: 20850817.
N. Nicolai, R. Miceli, A. Necchi, D. Biasoni i inni. Retroperitoneal lymph node dissection with no adjuvant chemotherapy in clinical stage I nonseminomatous germ cell tumours: long-term outcome and analysis of risk factors of recurrence. „Eur Urol”. 58 (6), s. 912–918, 2010. DOI: 10.1016/j.eururo.2010.08.032. PMID: 20817343.
S.D. Williams, D.M. Stablein, L.H. Einhorn, F.M. Muggia i inni. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. „N Engl J Med”. 317 (23), s. 1433–1438, 1987. DOI: 10.1056/NEJM198712033172303. PMID: 2446132.
G. Jayram, R.Z. Szmulewitz, S.E. Eggener. Management of good-risk metastatic nonseminomatous germ cell tumors of the testis: current concepts and controversies. „Indian J Urol”. 26 (1). s. 92–97. DOI: 10.4103/0970-1591.60449. PMID: 20535293.
L. Weissbach, R. Bussar-Maatz, H. Flechtner, U. Pichlmeier i inni. RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment. „Eur Urol”. 37 (5), s. 582–594, 2000. DOI: 10.1159/000020197. PMID: 10765098.
F. Rabbani, J. Sheinfeld, H. Farivar-Mohseni, A. Leon i inni. Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse. „J Clin Oncol”. 19 (7), s. 2020–2025, 2001. DOI: 10.1200/JCO.2001.19.7.2020. PMID: 11283135.
A.J. Stephenson, G.J. Bosl, D.F. Bajorin, J. Stasi i inni. Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion. „J Urol”. 174 (2), s. 557–560, 2005. DOI: 10.1097/01.ju.0000165163.03805.37. PMID: 16006891.
L.H. Einhorn, S.D. Williams, P.J. Loehrer, R. Birch i inni. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. „J Clin Oncol”. 7 (3), s. 387–391, 1989. DOI: 10.1200/JCO.1989.7.3.387. PMID: 2465391.
R. de Wit, G. Stoter, S.B. Kaye, D.T. Sleijfer i inni. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. „J Clin Oncol”. 15 (5), s. 1837–1843, 1997. DOI: 10.1200/JCO.1997.15.5.1837. PMID: 9164193.
A. Horwich, D.T. Sleijfer, S.D. Fosså, S.B. Kaye i inni. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. „J Clin Oncol”. 15 (5), s. 1844–1852, 1997. DOI: 10.1200/JCO.1997.15.5.1844. PMID: 9164194.
R. de Wit, J.T. Roberts, P.M. Wilkinson, P.H. de Mulder i inni. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. „J Clin Oncol”. 19 (6), s. 1629–1640, 2001. DOI: 10.1200/JCO.2001.19.6.1629. PMID: 11250991.
S. Culine, P. Kerbrat, A. Kramar, C. Théodore i inni. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). „Ann Oncol”. 18 (5), s. 917–924, 2007. DOI: 10.1093/annonc/mdm062. PMID: 17351252.
G.V. Kondagunta, J. Bacik, D. Bajorin, D. Dobrzynski i inni. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. „J Clin Oncol”. 23 (36), s. 9290–9294, 2005. DOI: 10.1200/JCO.2005.03.6616. PMID: 16361627.
C. Massard, A. Plantade, M. Gross-Goupil, Y. Loriot i inni. Poor prognosis nonseminomatous germ-cell tumours (NSGCTs): should chemotherapy doses be reduced at first cycle to prevent acute respiratory distress syndrome in patients with multiple lung metastases?. „Ann Oncol”. 21 (8), s. 1585–1588, 2010. DOI: 10.1093/annonc/mdq021. PMID: 20181575.
H.J. Lavery, R.R. Bahnson, D.S. Sharp, K.S. Pohar. Management of the residual post-chemotherapy retroperitoneal mass in germ cell tumors. „Ther Adv Urol”. 1 (4), s. 199–207, 2009. DOI: 10.1177/1756287209350315. PMID: 21789067.
B.S. Carver, A.M. Serio, D. Bajorin, R.J. Motzer i inni. Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors. „J Clin Oncol”. 25 (35), s. 5603–5608, 2007. DOI: 10.1200/JCO.2007.13.6283. PMID: 17998544.
H.G. Sim, P.H. Lange, D.W. Lin. Role of post-chemotherapy surgery in germ cell tumors. „Urol Clin North Am”. 34 (2), s. 199–217, 2007. DOI: 10.1016/j.ucl.2007.02.010. PMID: 17484925.
K. Oechsle, M. Hartmann, W. Brenner, S. Venz i inni. [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group. „J Clin Oncol”. 26 (36), s. 5930–5935, 2008. DOI: 10.1200/JCO.2008.17.1157. PMID: 19018083.
C. Kollmannsberger, S. Daneshmand, A. So, K.N. Chi i inni. Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery. „J Clin Oncol”. 28 (4), s. 537–542, 2010. DOI: 10.1200/JCO.2009.23.0755. PMID: 20026807.
K. Fizazi, J. Oldenburg, A. Dunant, I. Chen i inni. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. „Ann Oncol”. 19 (2), s. 259–264, 2008. DOI: 10.1093/annonc/mdm472. PMID: 18042838.
K. Fizazi, S. Tjulandin, R. Salvioni, J.R. Germà-Lluch i inni. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy-results from an international study group. „J Clin Oncol”. 19 (10), s. 2647–2657, 2001. DOI: 10.1200/JCO.2001.19.10.2647. PMID: 11352956.
D.R. Feldman, G.J. Bosl, J. Sheinfeld, R.J. Motzer. Medical treatment of advanced testicular cancer. „JAMA”. 299 (6), s. 672–684, 2008. DOI: 10.1001/jama.299.6.672. PMID: 18270356.
G.V. Kondagunta, J. Bacik, A. Donadio, D. Bajorin i inni. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. „J Clin Oncol”. 23 (27), s. 6549–6555, 2005. DOI: 10.1200/JCO.2005.19.638. PMID: 16170162.
P.J. Loehrer, R. Gonin, C.R. Nichols, T. Weathers i inni. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. „J Clin Oncol”. 16 (7), s. 2500–2504, 1998. DOI: 10.1200/JCO.1998.16.7.2500. PMID: 9667270.
A. Harstrick, H.J. Schmoll, H. Wilke, C.H. Köhne-Wömpner i inni. Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma. „J Clin Oncol”. 9 (9), s. 1549–1555, 1991. DOI: 10.1200/JCO.1991.9.9.1549. PMID: 1651992.
J.A. McCaffrey, M. Mazumdar, D.F. Bajorin, G.J. Bosl i inni. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. „J Clin Oncol”. 15 (7), s. 2559–2563, 1997. DOI: 10.1200/JCO.1997.15.7.2559. PMID: 9215825.
L. Popovic, G. Matovina-Brko, M. Popovic, D. Petrovic i inni. High dose chemotherapy with stem cell support in the treatment of testicular cancer. „World J Stem Cells”. 7 (11), s. 1222–1232, 2015. DOI: 10.4252/wjsc.v7.i11.1222. PMID: 26730267.
A. Lorch, A. Kleinhans, A. Kramar, C.K. Kollmannsberger i inni. Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial. „J Clin Oncol”. 30 (8), s. 800–805, 2012. DOI: 10.1200/JCO.2011.38.6391. PMID: 22291076.
L.H. Einhorn, S.D. Williams, A. Chamness, M.J. Brames i inni. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. „N Engl J Med”. 357 (4), s. 340–348, 2007. DOI: 10.1056/NEJMoa067749. PMID: 17652649.
J.L. Pico, G. Rosti, A. Kramar, H. Wandt i inni. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. „Ann Oncol”. 16 (7), s. 1152–1159, 2005. DOI: 10.1093/annonc/mdi228. PMID: 15928070.
A. Lorch, C. Kollmannsberger, J.T. Hartmann, B. Metzner i inni. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. „J Clin Oncol”. 25 (19), s. 2778–2784, 2007. DOI: 10.1200/JCO.2006.09.2148. PMID: 17602082.
A. Lorch, J. Beyer, C. Bascoul-Mollevi, A. Kramar i inni. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. „J Clin Oncol”. 28 (33), s. 4906–4911, 2010. DOI: 10.1200/JCO.2009.26.8128. PMID: 20956623.
K. Oechsle, A. Lorch, F. Honecker, C. Kollmannsberger i inni. Patterns of relapse after chemotherapy in patients with high-risk non-seminomatous germ cell tumor. „Oncology”. 78 (1), s. 47–53, 2010. DOI: 10.1159/000292358. PMID: 20215785.
A. Lorch, C. Bascoul-Mollevi, A. Kramar, L. Einhorn i inni. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. „J Clin Oncol”. 29 (16), s. 2178–2184, 2011. DOI: 10.1200/JCO.2010.32.6678. PMID: 21444870.
K. Oechsle, C. Kollmannsberger, F. Honecker, F. Mayer i inni. Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors. „Eur Urol”. 60 (4), s. 850–855, 2011. DOI: 10.1016/j.eururo.2011.06.019. PMID: 21704446.
N. Nicolai, A. Necchi, L. Gianni, L. Piva i inni. Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours. „BJU Int”. 104 (3), s. 340–346, 2009. DOI: 10.1111/j.1464-410X.2009.08453.x. PMID: 19239440.
W. Sui, D.C. Morrow, C.E. Bermejo, N.J. Hellenthal. Trends in Testicular Cancer Survival: A Large Population-based Analysis. „Urology”. 85 (6), s. 1394–1398, 2015. DOI: 10.1016/j.urology.2015.03.022. PMID: 26099885.
R.H. Verhoeven, A. Gondos, M.L. Janssen-Heijnen, K.U. Saum i inni. Testicular cancer in Europe and the USA: survival still rising among older patients. „Ann Oncol”. 24 (2), s. 508–513, 2013. DOI: 10.1093/annonc/mds460. PMID: 23110807.
N. Hanna, L.H. Einhorn. Testicular cancer: a reflection on 50 years of discovery. „J Clin Oncol”. 32 (28), s. 3085–3092, 2014. DOI: 10.1200/JCO.2014.56.0896. PMID: 25024068.
M.C. LI, R. Hertz, D.M. Bergenstal. Therapy of choriocarcinoma and related trophoblastic tumors with folic acid and purine antagonists. „N Engl J Med”. 259 (2), s. 66–74, 1958. DOI: 10.1056/NEJM195807102590204. PMID: 13566422.
J.D. Hainsworth, S.D. Williams, L.H. Einhorn, R. Birch i inni. Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin: results of a Southeastern Cancer Study Group trial. „J Clin Oncol”. 3 (5), s. 666–671, 1985. DOI: 10.1200/JCO.1985.3.5.666. PMID: 2582097.
G.J. Bosl, R. Gluckman, N.L. Geller, R.B. Golbey i inni. VAB-6: an effective chemotherapy regimen for patients with germ-cell tumors. „J Clin Oncol”. 4 (10), s. 1493–1499, 1986. DOI: 10.1200/JCO.1986.4.10.1493. PMID: 2428948.
G.J. Bosl, N.L. Geller, D. Bajorin, S.P. Leitner i inni. A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. „J Clin Oncol”. 6 (8), s. 1231–1238, 1988. DOI: 10.1200/JCO.1988.6.8.1231. PMID: 2457657.
S.D. Williams, R. Birch, L.H. Einhorn, L. Irwin i inni. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. „N Engl J Med”. 316 (23), s. 1435–1440, 1987. DOI: 10.1056/NEJM198706043162302. PMID: 2437455.
T. Shanmugalingam, A. Soultati, S. Chowdhury, S. Rudman i inni. Global incidence and outcome of testicular cancer. „Clin Epidemiol”. 5, s. 417–427, 2013. DOI: 10.2147/CLEP.S34430. PMID: 24204171.
C. La Vecchia, C. Bosetti, F. Lucchini, P. Bertuccio i inni. Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. „Ann Oncol”. 21 (6), s. 1323–1360, 2010. DOI: 10.1093/annonc/mdp530. PMID: 19948741.
K.A. McGlynn, B. Trabert. Adolescent and adult risk factors for testicular cancer. „Nat Rev Urol”. 9 (6), s. 339–349, 2012. DOI: 10.1038/nrurol.2012.61. PMID: 22508459.
B. Trabert, J. Chen, S.S. Devesa, F. Bray i inni. International patterns and trends in testicular cancer incidence, overall and by histologic subtype, 1973-2007. „Andrology”. 3 (1), s. 4–12, 2015. DOI: 10.1111/andr.293. PMID: 25331326.
M.J. Garner, M.C. Turner, P. Ghadirian, D. Krewski. Epidemiology of testicular cancer: an overview. „Int J Cancer”. 116 (3), s. 331–339, 2005. DOI: 10.1002/ijc.21032. PMID: 15818625.
S.M. Stevenson, W.T. Lowrance. Epidemiology and Diagnosis of Testis Cancer. „Urol Clin North Am”. 42 (3), s. 269–275, 2015. DOI: 10.1016/j.ucl.2015.04.001. PMID: 26216814.
A. Pettersson, L. Richiardi, A. Nordenskjold, M. Kaijser i inni. Age at surgery for undescended testis and risk of testicular cancer. „N Engl J Med”. 356 (18), s. 1835–1841, 2007. DOI: 10.1056/NEJMoa067588. PMID: 17476009.
C. Myrup, T.H. Schnack, J. Wohlfahrt. Correction of cryptorchidism and testicular cancer. „N Engl J Med”. 357 (8), s. 825–827, 2007. DOI: 10.1056/NEJMc071510. PMID: 17715418.
K.P. Dieckmann, U. Pichlmeier. Clinical epidemiology of testicular germ cell tumors. „World J Urol”. 22 (1), s. 2–14, 2004. DOI: 10.1007/s00345-004-0398-8. PMID: 15034740.
S.D. Fosså, J. Chen, S.J. Schonfeld, K.A. McGlynn i inni. Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men. „J Natl Cancer Inst”. 97 (14), s. 1056–1066, 2005. DOI: 10.1093/jnci/dji185. PMID: 16030303.
A. Osterlind, J.G. Berthelsen, N. Abildgaard, S.O. Hansen i inni. Risk of bilateral testicular germ cell cancer in Denmark: 1960-1984. „J Natl Cancer Inst”. 83 (19), s. 1391–1395, 1991. PMID: 1656057.
K.P. Dieckmann, V. Loy. Prevalence of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasms. „J Clin Oncol”. 14 (12), s. 3126–3132, 1996. DOI: 10.1200/JCO.1996.14.12.3126. PMID: 8955658.
H. von der Maase, M. Rørth, S. Walbom-Jørgensen, B.L. Sørensen i inni. Carcinoma in situ of contralateral testis in patients with testicular germ cell cancer: study of 27 cases in 500 patients. „Br Med J (Clin Res Ed)”. 293 (6559), s. 1398–1401, 1986. PMID: 3026550.
K. Hemminki, X. Li. Familial risk in testicular cancer as a clue to a heritable and environmental aetiology. „Br J Cancer”. 90 (9), s. 1765–1770, 2004. DOI: 10.1038/sj.bjc.6601714. PMID: 15208620.
K.P. Dieckmann, U. Pichlmeier. The prevalence of familial testicular cancer: an analysis of two patient populations and a review of the literature. „Cancer”. 80 (10), s. 1954–1960, 1997. PMID: 9366298.
K. Hemminki, K. Czene. Attributable risks of familial cancer from the Family-Cancer Database. „Cancer Epidemiol Biomarkers Prev”. 11 (12), s. 1638–1644, 2002. PMID: 12496055.
K. Hemminki, X. Li. Cancer risks in twins: results from the Swedish family-cancer database. „Int J Cancer”. 99 (6), s. 873–878, Jun 2002. DOI: 10.1002/ijc.10441. PMID: 12115491.
A.J. Swerdlow, B.L. De Stavola, M.A. Swanwick, N.E. Maconochie. Risks of breast and testicular cancers in young adult twins in England and Wales: evidence on prenatal and genetic aetiology. „Lancet”. 350 (9093), s. 1723–1728, 1997. PMID: 9413462.
M.M. Braun, A. Ahlbom, B. Floderus, L.A. Brinton i inni. Effect of twinship on incidence of cancer of the testis, breast, and other sites (Sweden). „Cancer Causes Control”. 6 (6), s. 519–524, 1995. PMID: 8580300.
V.P. Doria-Rose, M.L. Biggs, N.S. Weiss. Subfertility and the risk of testicular germ cell tumors (United States). „Cancer Causes Control”. 16 (6), s. 651–656, 2005. DOI: 10.1007/s10552-005-0169-x. PMID: 16049803.
J.D. Raman, C.F. Nobert, M. Goldstein. Increased incidence of testicular cancer in men presenting with infertility and abnormal semen analysis. „J Urol”. 174 (5), s. 1819–1822, Nov 2005. DOI: 10.1097/01.ju.0000177491.98461.aa. PMID: 16217294.
M. Mancini, L. Carmignani, G. Gazzano, P. Sagone i inni. High prevalence of testicular cancer in azoospermic men without spermatogenesis. „Hum Reprod”. 22 (4), s. 1042–1046, 2007. DOI: 10.1093/humrep/del500. PMID: 17220165.
M. Kathrins, T.F. Kolon. Malignancy in disorders of sex development. „Transl Androl Urol”. 5 (5), s. 794–798, 2016. DOI: 10.21037/tau.2016.08.09. PMID: 27785439.
R. Hersmus, H. Stoop, S.J. White, S.L. Drop i inni. Delayed Recognition of Disorders of Sex Development (DSD): A Missed Opportunity for Early Diagnosis of Malignant Germ Cell Tumors. „Int J Endocrinol”. 2012, 2012. DOI: 10.1155/2012/671209. PMID: 22315593.
J. Pleskacova, R. Hersmus, J.W. Oosterhuis, B.A. Setyawati i inni. Tumor risk in disorders of sex development. „Sex Dev”. 4 (4–5), s. 259–269, Sep 2010. DOI: 10.1159/000314536. PMID: 20558977.
M.M. Joki-Erkkilä, R. Karikoski, I. Rantala, H.L. Lenko i inni. Gonadoblastoma and dysgerminoma associated with XY gonadal dysgenesis in an adolescent with chronic renal failure: a case of Frasier syndrome. „J Pediatr Adolesc Gynecol”. 15 (3), s. 145–149, 2002. PMID: 12106750.
J. Pelletier, W. Bruening, C.E. Kashtan, S.M. Mauer i inni. Germline mutations in the Wilms’ tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. „Cell”. 67 (2), s. 437–447, 1991. PMID: 1655284.
L.H. Looijenga, R. Hersmus, J.W. Oosterhuis, M. Cools i inni. Tumor risk in disorders of sex development (DSD). „Best Pract Res Clin Endocrinol Metab”. 21 (3), s. 480–495, 2007. DOI: 10.1016/j.beem.2007.05.001. PMID: 17875493.
G. Accardo, G. Vallone, D. Esposito, F. Barbato i inni. Testicular parenchymal abnormalities in Klinefelter syndrome: a question of cancer? Examination of 40 consecutive patients. „Asian J Androl”. 17 (1). s. 154–158. DOI: 10.4103/1008-682X.128514. PMID: 25130577.
H. Hasle, A. Mellemgaard, J. Nielsen, J. Hansen. Cancer incidence in men with Klinefelter syndrome. „Br J Cancer”. 71 (2), s. 416–420, 1995. PMID: 7841064.
H.T. Heller, M.C. Oliff, P.M. Doubilet, M.P. O’Leary i inni. Testicular microlithiasis: prevalence and association with primary testicular neoplasm. „J Clin Ultrasound”. 42 (7), s. 423–426, 2014. DOI: 10.1002/jcu.22144. PMID: 24585495.
M.L. Cooper, M. Kaefer, R. Fan, R.C. Rink i inni. Testicular microlithiasis in children and associated testicular cancer. „Radiology”. 270 (3), s. 857–863, 2014. DOI: 10.1148/radiol.13130394. PMID: 24475810.
B.J. DeCastro, A.C. Peterson, R.A. Costabile. A 5-year followup study of asymptomatic men with testicular microlithiasis. „J Urol”. 179 (4), s. 1420–1423, 2008. DOI: 10.1016/j.juro.2007.11.080. PMID: 18289592.
D.A. Hill, G. Gridley, S. Cnattingius, L. Mellemkjaer i inni. Mortality and cancer incidence among individuals with Down syndrome. „Arch Intern Med”. 163 (6), s. 705–711, 2003. PMID: 12639204.
K. Patja, E. Pukkala, R. Sund, M. Iivanainen i inni. Cancer incidence of persons with Down syndrome in Finland: a population-based study. „Int J Cancer”. 118 (7), s. 1769–1772, 2006. DOI: 10.1002/ijc.21518. PMID: 16231334.
H. Hasle, J.M. Friedman, J.H. Olsen, S.A. Rasmussen. Low risk of solid tumors in persons with Down syndrome. „Genet Med”. 18 (11), s. 1151–1157, 2016. DOI: 10.1038/gim.2016.23. PMID: 27031084.
T.P. Cooley. Non-AIDS-defining cancer in HIV-infected people. „Hematol Oncol Clin North Am”. 17 (3), s. 889–899, 2003. PMID: 12852661.
J.J. Goedert, M.P. Purdue, T.S. McNeel, K.A. McGlynn i inni. Risk of germ cell tumors among men with HIV/acquired immunodeficiency syndrome. „Cancer Epidemiol Biomarkers Prev”. 16 (6), s. 1266–1269, 2007. DOI: 10.1158/1055-9965.EPI-07-0042. PMID: 17548695.
M. Frisch, R.J. Biggar, E.A. Engels, J.J. Goedert. Association of cancer with AIDS-related immunosuppression in adults. „JAMA”. 285 (13), s. 1736–1745, 2001. PMID: 11277828.
J.J. Goedert, T.R. Coté, P. Virgo, S.M. Scoppa i inni. Spectrum of AIDS-associated malignant disorders. „Lancet”. 351 (9119), s. 1833–1839, 1998. PMID: 9652666.
K. Lin, R. Sharangpani. Screening for testicular cancer: an evidence review for the U.S. Preventive Services Task Force. „Ann Intern Med”. 153 (6), s. 396–399, 2010. DOI: 10.7326/0003-4819-153-6-201009210-00007. PMID: 20855803.
S.A. Giralt, F. Dexeus, R. Amato, A. Sella i inni. Hyperthyroidism in men with germ cell tumors and high levels of beta-human chorionic gonadotropin. „Cancer”. 69 (5), s. 1286–1290, 1992. PMID: 1371235.
S.F. Oosting, E.C. de Haas, T.P. Links, D. de Bruin i inni. Prevalence of paraneoplastic hyperthyroidism in patients with metastatic non-seminomatous germ-cell tumors. „Ann Oncol”. 21 (1), s. 104–108, 2010. DOI: 10.1093/annonc/mdp265. PMID: 19605510.
A.A. Borski. Proceedings: Diagnosis, staging, and natural history of testicular tumors. „Cancer”. 32 (5), s. 1202–1205, 1973. PMID: 4757911.
J.E. Elzinga-Tinke, G.R. Dohle, L.H. Looijenga. Etiology and early pathogenesis of malignant testicular germ cell tumors: towards possibilities for preinvasive diagnosis. „Asian J Androl”. 17 (3). s. 381–393. DOI: 10.4103/1008-682X.148079. PMID: 25791729.
N.E. Skakkebaek, E. Rajpert-De Meyts, N. Jørgensen, E. Carlsen i inni. Germ cell cancer and disorders of spermatogenesis: an environmental connection?. „APMIS”. 106 (1), s. 3–11, 1998. PMID: 9524557.
R.S. Chaganti, J. Houldsworth. The cytogenetic theory of the pathogenesis of human adult male germ cell tumors. Review article. „APMIS”. 106 (1), s. 80–83, 1998. PMID: 9524565.
B. Boldajipour, E. Raz. What is left behind--quality control in germ cell migration. „Sci STKE”. 2007 (383), 2007. DOI: 10.1126/stke.3832007pe16. PMID: 17456805.
L.H. Looijenga, H. de Leeuw, M. van Oorschot, R.J. van Gurp i inni. Stem cell factor receptor (c-KIT) codon 816 mutations predict development of bilateral testicular germ-cell tumors. „Cancer Res”. 63 (22), s. 7674–7678, 2003. PMID: 14633689.
E.A. Rapley, C. Turnbull, A.A. Al Olama, E.T. Dermitzakis i inni. A genome-wide association study of testicular germ cell tumor. „Nat Genet”. 41 (7), s. 807–810, 2009. DOI: 10.1038/ng.394. PMID: 19483681.
P.A. Kanetsky, N. Mitra, S. Vardhanabhuti, M. Li i inni. Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. „Nat Genet”. 41 (7), s. 811–815, 2009. DOI: 10.1038/ng.393. PMID: 19483682.
A. McIntyre, B. Summersgill, B. Grygalewicz, A.J. Gillis i inni. Amplification and overexpression of the KIT gene is associated with progression in the seminoma subtype of testicular germ cell tumors of adolescents and adults. „Cancer Res”. 65 (18), s. 8085–8089, 2005. DOI: 10.1158/0008-5472.CAN-05-0471. PMID: 16166280.
M. Studniarek, K. Skrobisz-Balandowska, E. Modzelewska. Scrotal imaging. „J Ultrason”. 15 (62), s. 245–258, 2015. DOI: 10.15557/JoU.2015.0021. PMID: 26674847.
G.W. Barrisford, E.I. Kreydin, M.A. Preston, D. Rodriguez i inni. Role of imaging in testicular cancer: current and future practice. „Future Oncol”. 11 (18), s. 2575–2586, 2015. DOI: 10.2217/fon.15.194. PMID: 26314944.
M.D. Rifkin, A.B. Kurtz, M.E. Pasto, B.B. Goldberg. Diagnostic capabilities of high-resolution scrotal ultrasonography: prospective evaluation. „J Ultrasound Med”. 4 (1), s. 13–19, Jan 1985. PMID: 3882978.
S. Hilton, H.W. Herr, J.B. Teitcher, C.B. Begg i inni. CT detection of retroperitoneal lymph node metastases in patients with clinical stage I testicular nonseminomatous germ cell cancer: assessment of size and distribution criteria. „AJR Am J Roentgenol”. 169 (2), s. 521–525, 1997. DOI: 10.2214/ajr.169.2.9242768. PMID: 9242768.
E.I. Kreydin, G.W. Barrisford, A.S. Feldman, M.A. Preston. Testicular cancer: what the radiologist needs to know. „AJR Am J Roentgenol”. 200 (6), s. 1215–1225, 2013. DOI: 10.2214/AJR.12.10319. PMID: 23701056.
S.A. Sohaib, D.M. Koh, Y. Barbachano, J. Parikh i inni. Prospective assessment of MRI for imaging retroperitoneal metastases from testicular germ cell tumours. „Clin Radiol”. 64 (4), s. 362–367, 2009. DOI: 10.1016/j.crad.2008.10.011. PMID: 19264179.
J.H. Ellis, J.R. Bies, K.K. Kopecky, E.C. Klatte i inni. Comparison of NMR and CT imaging in the evaluation of metastatic retroperitoneal lymphadenopathy from testicular carcinoma. „J Comput Assist Tomogr”. 8 (4), s. 709–719, 1984. PMID: 6539790.
M. de Wit, W. Brenner, M. Hartmann, J. Kotzerke i inni. [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial. „Ann Oncol”. 19 (9), s. 1619–1623, 2008. DOI: 10.1093/annonc/mdn170. PMID: 18453520.
R.A. Huddart, M.J. O’Doherty, A. Padhani, G.J. Rustin i inni. 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group. „J Clin Oncol”. 25 (21), s. 3090–3095, 2007. DOI: 10.1200/JCO.2006.09.3831. PMID: 17634488.
M. De Santis, A. Becherer, C. Bokemeyer, F. Stoiber i inni. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. „J Clin Oncol”. 22 (6), s. 1034–1039, 2004. DOI: 10.1200/JCO.2004.07.188. PMID: 15020605.
C. Winter, P. Albers. Testicular germ cell tumors: pathogenesis, diagnosis and treatment. „Nat Rev Endocrinol”. 7 (1), s. 43–53, 2011. DOI: 10.1038/nrendo.2010.196. PMID: 21116298.
M.C. Mir, N. Pavan, M.L. Gonzalgo. Current Clinical Applications of Testicular Cancer Biomarkers. „Urol Clin North Am”. 43 (1), s. 119–125, 2016. DOI: 10.1016/j.ucl.2015.08.011. PMID: 26614034.
J.C. Milose, C.P. Filson, A.Z. Weizer, K.S. Hafez i inni. Role of biochemical markers in testicular cancer: diagnosis, staging, and surveillance. „Open Access J Urol”. 4, s. 1–8, 2011. DOI: 10.2147/OAJU.S15063. PMID: 24198649.
S.M. Pearce, S.L. Liauw, S.E. Eggener. Management of Low-Stage Testicular Seminoma. „Urol Clin North Am”. 42 (3), s. 287–298, 2015. DOI: 10.1016/j.ucl.2015.04.003. PMID: 26216816.
M. Chovanec, N. Hanna, K.C. Cary, L. Einhorn i inni. Management of stage I testicular germ cell tumours. „Nat Rev Urol”. 13 (11), s. 663–673, 2016. DOI: 10.1038/nrurol.2016.164. PMID: 27618772.
E. Rajpert-De Meyts, K.A. McGlynn, K. Okamoto, M.A. Jewett i inni. Testicular germ cell tumours. „Lancet”. 387 (10029), s. 1762–1774, 2016. DOI: 10.1016/S0140-6736(15)00991-5. PMID: 26651223.
R.J. Groll, P. Warde, M.A. Jewett. A comprehensive systematic review of testicular germ cell tumor surveillance. „Crit Rev Oncol Hematol”. 64 (3), s. 182–197, 2007. DOI: 10.1016/j.critrevonc.2007.04.014. PMID: 17644403.
J. Aparicio, X. García del Muro, P. Maroto, L. Paz-Ares i inni. Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. „Ann Oncol”. 14 (6), s. 867–872, 2003. PMID: 12796024.
P. Warde, L. Specht, A. Horwich, T. Oliver i inni. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. „J Clin Oncol”. 20 (22), s. 4448–4452, 2002. DOI: 10.1200/JCO.2002.01.038. PMID: 12431967.
P. Chung, C. Parker, T. Panzarella, M.K. Gospodarowicz i inni. Surveillance in stage I testicular seminoma – risk of late relapse. „Can J Urol”. 9 (5), s. 1637–1640, 2002. PMID: 12431325.
J. Aparicio, P. Maroto, X. García del Muro, A. Sánchez-Muñoz i inni. Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG). „Ann Oncol”. 25 (11), s. 2173–2178, 2014. DOI: 10.1093/annonc/mdu437. PMID: 25210015.
T. Tandstad, O. Ståhl, O. Dahl, H.S. Haugnes i inni. Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA). „Ann Oncol”. 27 (7), s. 1299–1304, 2016. DOI: 10.1093/annonc/mdw164. PMID: 27052649.
P. Warde, M.K. Gospodarowicz, D. Banerjee, T. Panzarella i inni. Prognostic factors for relapse in stage I testicular seminoma treated with surveillance. „J Urol”. 157 (5), s. 1705–1709, 1997. PMID: 9112510.
P. Chung, G. Daugaard, S. Tyldesley, E.G. Atenafu i inni. Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance. „Cancer Med”. 4 (1), s. 155–160, 2015. DOI: 10.1002/cam4.324. PMID: 25236854.
P. Chung, P. Warde. Stage I seminoma: adjuvant treatment is effective but is it necessary?. „J Natl Cancer Inst”. 103 (3), s. 194–196, 2011. DOI: 10.1093/jnci/djq535. PMID: 21212383.
T. Tandstad, R. Smaaland, A. Solberg, R.M. Bremnes i inni. Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group. „J Clin Oncol”. 29 (6), s. 719–725, 2011. DOI: 10.1200/JCO.2010.30.1044. PMID: 21205748.
R.T. Oliver, G.M. Mead, G.J. Rustin, J.K. Joffe i inni. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). „J Clin Oncol”. 29 (8), s. 957–962, 2011. DOI: 10.1200/JCO.2009.26.4655. PMID: 21282539.
R.T. Oliver, M.D. Mason, G.M. Mead, H. von der Maase i inni. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. „Lancet”. 366 (9482). s. 293–300. DOI: 10.1016/S0140-6736(05)66984-X. PMID: 16039331.
J. Aparicio, J.R. Germà, X. García del Muro, P. Maroto i inni. Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. „J Clin Oncol”. 23 (34), s. 8717–8723, 2005. DOI: 10.1200/JCO.2005.01.9810. PMID: 16260698.
J. Aparicio, P. Maroto, X.G. del Muro, J. Gumà i inni. Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study. „J Clin Oncol”. 29 (35), s. 4677–4681, 2011. DOI: 10.1200/JCO.2011.36.0503. PMID: 22042940.
W.G. Jones, S.D. Fossa, G.M. Mead, J.T. Roberts i inni. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). „J Clin Oncol”. 23 (6), s. 1200–1208, 2005. DOI: 10.1200/JCO.2005.08.003. PMID: 15718317.
S.D. Fosså, A. Horwich, J.M. Russell, J.T. Roberts i inni. Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. „J Clin Oncol”. 17 (4), s. 1146, 1999. DOI: 10.1200/JCO.1999.17.4.1146. PMID: 10561173.
N. Boujelbene, A. Cosinschi, N. Boujelbene, K. Khanfir i inni. Pure seminoma: a review and update. „Radiat Oncol”. 6, s. 90, 2011. DOI: 10.1186/1748-717X-6-90. PMID: 21819630.
P.W. Chung, M.K. Gospodarowicz, T. Panzarella, M.A. Jewett i inni. Stage II testicular seminoma: patterns of recurrence and outcome of treatment. „Eur Urol”. 45 (6), s. 754–759, 2004. DOI: 10.1016/j.eururo.2004.01.020. PMID: 15149748.
J. Classen, H. Schmidberger, C. Meisner, R. Souchon i inni. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. „J Clin Oncol”. 21 (6), s. 1101–1106, 2003. DOI: 10.1200/JCO.2003.06.065. PMID: 12637477.
J. Domont, C. Massard, A. Patrikidou, A. Bossi i inni. A risk-adapted strategy of radiotherapy or cisplatin-based chemotherapy in stage II seminoma. „Urol Oncol”. 31 (5), s. 697–705, 2013. DOI: 10.1016/j.urolonc.2011.04.004. PMID: 21665493.
X. Garcia-del-Muro, P. Maroto, J. Gumà, J. Sastre i inni. Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study. „J Clin Oncol”. 26 (33), s. 5416–5421, 2008. DOI: 10.1200/JCO.2007.15.9103. PMID: 18936476.
S. Krege, C. Boergermann, R. Baschek, A. Hinke i inni. Single agent carboplatin for CS IIA/B testicular seminoma. A phase II study of the German Testicular Cancer Study Group (GTCSG). „Ann Oncol”. 17 (2), s. 276–280, 2006. DOI: 10.1093/annonc/mdj039. PMID: 16254023.
S. Hinz, M. Schrader, C. Kempkensteffen, R. Bares i inni. The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma. „J Urol”. 179 (3), s. 936–940, 2008. DOI: 10.1016/j.juro.2007.10.054. PMID: 18207171.
A. Becherer, M. De Santis, G. Karanikas, M. Szabó i inni. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals. „Eur J Radiol”. 54 (2), s. 284–288, 2005. DOI: 10.1016/j.ejrad.2004.07.012. PMID: 15837411.
Y. Ehrlich, M.J. Brames, S.D. Beck, R.S. Foster i inni. Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission?. „J Clin Oncol”. 28 (4), s. 531–536, 2010. DOI: 10.1200/JCO.2009.23.0714. PMID: 20026808.
S. Culine, C. Theodore, M.J. Terrier-Lacombe, J.P. Droz. Primary chemotherapy in patients with nonseminomatous germ cell tumors of the testis and biological disease only after orchiectomy. „J Urol”. 155 (4), s. 1296–1298, 1996. PMID: 8632558.
B.E. Davis, H.W. Herr, W.R. Fair, G.J. Bosl. The management of patients with nonseminomatous germ cell tumors of the testis with serologic disease only after orchiectomy. „J Urol”. 152 (1), s. 111–113, 1994. PMID: 7515445.
G. Read, S.P. Stenning, M.H. Cullen, M.C. Parkinson i inni. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. „J Clin Oncol”. 10 (11), s. 1762–1768, 1992. DOI: 10.1200/JCO.1992.10.11.1762. PMID: 1403057.
L.S. Freedman, M.C. Parkinson, W.G. Jones, R.T. Oliver i inni. Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. „Lancet”. 2 (8554), s. 294–298, 1987. PMID: 2886764.
J.F. Sturgeon, M.J. Moore, D.M. Kakiashvili, I. Duran i inni. Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital’s experience. „Eur Urol”. 59 (4), s. 556–562, 2011. DOI: 10.1016/j.eururo.2010.12.010. PMID: 21190791.
C. Kollmannsberger, C. Moore, K.N. Chi, N. Murray i inni. Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy. „Ann Oncol”. 21 (6), s. 1296–1301, 2010. DOI: 10.1093/annonc/mdp473. PMID: 19875756.
M.H. Cullen, S.P. Stenning, M.C. Parkinson, S.D. Fossa i inni. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. „J Clin Oncol”. 14 (4), s. 1106–1113, 1996. DOI: 10.1200/JCO.1996.14.4.1106. PMID: 8648364.
J. Pont, W. Albrecht, G. Postner, F. Sellner i inni. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. „J Clin Oncol”. 14 (2), s. 441–448, 1996. DOI: 10.1200/JCO.1996.14.2.441. PMID: 8636755.
C. Chevreau, C. Mazerolles, M. Soulié, M.H. Gaspard i inni. Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion. „Eur Urol”. 46 (2), s. 209–214, 2004. DOI: 10.1016/j.eururo.2004.03.022. PMID: 15245815.
R.T. Oliver, J. Ong, J. Shamash, R. Ravi i inni. Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with Stage 1 nonseminoma treated with adjuvant chemotherapy. „Urology”. 63 (3), s. 556–561, 2004. DOI: 10.1016/j.urology.2003.10.023. PMID: 15028457.
D. Böhlen, M. Borner, R.W. Sonntag, M.F. Fey i inni. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. „J Urol”. 161 (4), s. 1148–1152, 1999. PMID: 10081858.
T. Tandstad, O. Ståhl, U. Håkansson, O. Dahl i inni. One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group. „Ann Oncol”. 25 (11), s. 2167–2172, 2014. DOI: 10.1093/annonc/mdu375. PMID: 25114021.
P. Albers, R. Siener, S. Krege, H.U. Schmelz i inni. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. „J Clin Oncol”. 26 (18), s. 2966–2972, 2008. DOI: 10.1200/JCO.2007.12.0899. PMID: 18458040.
C.J. Sweeney, B.P. Hermans, D.K. Heilman, R.S. Foster i inni. Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma-predominant testis cancer. „J Clin Oncol”. 18 (2), s. 358–362, 2000. DOI: 10.1200/JCO.2000.18.2.358. PMID: 10637250.
A. Heidenreich, P. Albers, M. Hartmann, S. Kliesch i inni. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. „J Urol”. 169 (5), s. 1710–1714, 2003. DOI: 10.1097/01.ju.0000060960.18092.54. PMID: 12686815.
A. Heidenreich, D. Pfister. Retroperitoneal lymphadenectomy and resection for testicular cancer: an update on best practice. „Ther Adv Urol”. 4 (4), s. 187–205, 2012. DOI: 10.1177/1756287212443170. PMID: 22852029.
S.D. Beck, A.L. Bey, R. Bihrle, R.S. Foster. Ejaculatory status and fertility rates after primary retroperitoneal lymph node dissection. „J Urol”. 184 (5), s. 2078–2080, Nov 2010. DOI: 10.1016/j.juro.2010.06.146. PMID: 20850817.
N. Nicolai, R. Miceli, A. Necchi, D. Biasoni i inni. Retroperitoneal lymph node dissection with no adjuvant chemotherapy in clinical stage I nonseminomatous germ cell tumours: long-term outcome and analysis of risk factors of recurrence. „Eur Urol”. 58 (6), s. 912–918, 2010. DOI: 10.1016/j.eururo.2010.08.032. PMID: 20817343.
J.P. Donohue, J.A. Thornhill, R.S. Foster, R. Bihrle i inni. The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: the Indiana University experience (1965 to 1989). „J Urol”. 153 (1), s. 85–89, 1995. PMID: 7966799.
S.D. Williams, D.M. Stablein, L.H. Einhorn, F.M. Muggia i inni. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. „N Engl J Med”. 317 (23), s. 1433–1438, 1987. DOI: 10.1056/NEJM198712033172303. PMID: 2446132.
A. Horwich, A. Norman, C. Fisher, W.F. Hendry i inni. Primary chemotherapy for stage II nonseminomatous germ cell tumors of the testis. „J Urol”. 151 (1), s. 72–77, 1994. PMID: 8254836.
G. Jayram, R.Z. Szmulewitz, S.E. Eggener. Management of good-risk metastatic nonseminomatous germ cell tumors of the testis: current concepts and controversies. „Indian J Urol”. 26 (1). s. 92–97. DOI: 10.4103/0970-1591.60449. PMID: 20535293.
L. Weissbach, R. Bussar-Maatz, H. Flechtner, U. Pichlmeier i inni. RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment. „Eur Urol”. 37 (5), s. 582–594, 2000. DOI: 10.1159/000020197. PMID: 10765098.
F. Rabbani, J. Sheinfeld, H. Farivar-Mohseni, A. Leon i inni. Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse. „J Clin Oncol”. 19 (7), s. 2020–2025, 2001. DOI: 10.1200/JCO.2001.19.7.2020. PMID: 11283135.
A.J. Stephenson, G.J. Bosl, D.F. Bajorin, J. Stasi i inni. Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion. „J Urol”. 174 (2), s. 557–560, 2005. DOI: 10.1097/01.ju.0000165163.03805.37. PMID: 16006891.
L.H. Einhorn, S.D. Williams, P.J. Loehrer, R. Birch i inni. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. „J Clin Oncol”. 7 (3), s. 387–391, 1989. DOI: 10.1200/JCO.1989.7.3.387. PMID: 2465391.
R. de Wit, G. Stoter, S.B. Kaye, D.T. Sleijfer i inni. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. „J Clin Oncol”. 15 (5), s. 1837–1843, 1997. DOI: 10.1200/JCO.1997.15.5.1837. PMID: 9164193.
A. Horwich, D.T. Sleijfer, S.D. Fosså, S.B. Kaye i inni. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. „J Clin Oncol”. 15 (5), s. 1844–1852, 1997. DOI: 10.1200/JCO.1997.15.5.1844. PMID: 9164194.
R. de Wit, J.T. Roberts, P.M. Wilkinson, P.H. de Mulder i inni. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. „J Clin Oncol”. 19 (6), s. 1629–1640, 2001. DOI: 10.1200/JCO.2001.19.6.1629. PMID: 11250991.
S. Culine, P. Kerbrat, A. Kramar, C. Théodore i inni. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). „Ann Oncol”. 18 (5), s. 917–924, 2007. DOI: 10.1093/annonc/mdm062. PMID: 17351252.
R.H. Jones, P.A. Vasey. Part II: testicular cancer-management of advanced disease. „Lancet Oncol”. 4 (12), s. 738–747, 2003. PMID: 14662430.
G.V. Kondagunta, J. Bacik, D. Bajorin, D. Dobrzynski i inni. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. „J Clin Oncol”. 23 (36), s. 9290–9294, 2005. DOI: 10.1200/JCO.2005.03.6616. PMID: 16361627.
R. de Wit, G. Stoter, D.T. Sleijfer, J.P. Neijt i inni. Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. „Br J Cancer”. 78 (6), s. 828–832, 1998. PMID: 9743309.
C. Massard, A. Plantade, M. Gross-Goupil, Y. Loriot i inni. Poor prognosis nonseminomatous germ-cell tumours (NSGCTs): should chemotherapy doses be reduced at first cycle to prevent acute respiratory distress syndrome in patients with multiple lung metastases?. „Ann Oncol”. 21 (8), s. 1585–1588, 2010. DOI: 10.1093/annonc/mdq021. PMID: 20181575.
H.J. Lavery, R.R. Bahnson, D.S. Sharp, K.S. Pohar. Management of the residual post-chemotherapy retroperitoneal mass in germ cell tumors. „Ther Adv Urol”. 1 (4), s. 199–207, 2009. DOI: 10.1177/1756287209350315. PMID: 21789067.
B.S. Carver, A.M. Serio, D. Bajorin, R.J. Motzer i inni. Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors. „J Clin Oncol”. 25 (35), s. 5603–5608, 2007. DOI: 10.1200/JCO.2007.13.6283. PMID: 17998544.
H.G. Sim, P.H. Lange, D.W. Lin. Role of post-chemotherapy surgery in germ cell tumors. „Urol Clin North Am”. 34 (2), s. 199–217, 2007. DOI: 10.1016/j.ucl.2007.02.010. PMID: 17484925.
K. Oechsle, M. Hartmann, W. Brenner, S. Venz i inni. [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group. „J Clin Oncol”. 26 (36), s. 5930–5935, 2008. DOI: 10.1200/JCO.2008.17.1157. PMID: 19018083.
C. Kollmannsberger, S. Daneshmand, A. So, K.N. Chi i inni. Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery. „J Clin Oncol”. 28 (4), s. 537–542, 2010. DOI: 10.1200/JCO.2009.23.0755. PMID: 20026807.
K. Fizazi, J. Oldenburg, A. Dunant, I. Chen i inni. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. „Ann Oncol”. 19 (2), s. 259–264, 2008. DOI: 10.1093/annonc/mdm472. PMID: 18042838.
K. Fizazi, S. Tjulandin, R. Salvioni, J.R. Germà-Lluch i inni. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy-results from an international study group. „J Clin Oncol”. 19 (10), s. 2647–2657, 2001. DOI: 10.1200/JCO.2001.19.10.2647. PMID: 11352956.
D.R. Feldman, G.J. Bosl, J. Sheinfeld, R.J. Motzer. Medical treatment of advanced testicular cancer. „JAMA”. 299 (6), s. 672–684, 2008. DOI: 10.1001/jama.299.6.672. PMID: 18270356.
G.V. Kondagunta, J. Bacik, A. Donadio, D. Bajorin i inni. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. „J Clin Oncol”. 23 (27), s. 6549–6555, 2005. DOI: 10.1200/JCO.2005.19.638. PMID: 16170162.
P.J. Loehrer, R. Gonin, C.R. Nichols, T. Weathers i inni. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. „J Clin Oncol”. 16 (7), s. 2500–2504, 1998. DOI: 10.1200/JCO.1998.16.7.2500. PMID: 9667270.
A. Harstrick, H.J. Schmoll, H. Wilke, C.H. Köhne-Wömpner i inni. Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma. „J Clin Oncol”. 9 (9), s. 1549–1555, 1991. DOI: 10.1200/JCO.1991.9.9.1549. PMID: 1651992.
J.A. McCaffrey, M. Mazumdar, D.F. Bajorin, G.J. Bosl i inni. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. „J Clin Oncol”. 15 (7), s. 2559–2563, 1997. DOI: 10.1200/JCO.1997.15.7.2559. PMID: 9215825.
R.J. Motzer, D.F. Bajorin, V. Vlamis, S. Weisen i inni. Ifosfamide-based chemotherapy for patients with resistant germ cell tumors: the Memorial Sloan-Kettering Cancer Center experience. „Semin Oncol”. 19 (6 Suppl 12), s. 8–11, 1992. PMID: 1336624.
P.J. Loehrer, R. Lauer, B.J. Roth, S.D. Williams i inni. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. „Ann Intern Med”. 109 (7), s. 540–546, 1988. PMID: 2844110.
L. Popovic, G. Matovina-Brko, M. Popovic, D. Petrovic i inni. High dose chemotherapy with stem cell support in the treatment of testicular cancer. „World J Stem Cells”. 7 (11), s. 1222–1232, 2015. DOI: 10.4252/wjsc.v7.i11.1222. PMID: 26730267.
A. Lorch, A. Kleinhans, A. Kramar, C.K. Kollmannsberger i inni. Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial. „J Clin Oncol”. 30 (8), s. 800–805, 2012. DOI: 10.1200/JCO.2011.38.6391. PMID: 22291076.
L.H. Einhorn, S.D. Williams, A. Chamness, M.J. Brames i inni. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. „N Engl J Med”. 357 (4), s. 340–348, 2007. DOI: 10.1056/NEJMoa067749. PMID: 17652649.
J.L. Pico, G. Rosti, A. Kramar, H. Wandt i inni. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. „Ann Oncol”. 16 (7), s. 1152–1159, 2005. DOI: 10.1093/annonc/mdi228. PMID: 15928070.
A. Lorch, C. Kollmannsberger, J.T. Hartmann, B. Metzner i inni. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. „J Clin Oncol”. 25 (19), s. 2778–2784, 2007. DOI: 10.1200/JCO.2006.09.2148. PMID: 17602082.
A. Lorch, J. Beyer, C. Bascoul-Mollevi, A. Kramar i inni. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. „J Clin Oncol”. 28 (33), s. 4906–4911, 2010. DOI: 10.1200/JCO.2009.26.8128. PMID: 20956623.
K. Oechsle, A. Lorch, F. Honecker, C. Kollmannsberger i inni. Patterns of relapse after chemotherapy in patients with high-risk non-seminomatous germ cell tumor. „Oncology”. 78 (1), s. 47–53, 2010. DOI: 10.1159/000292358. PMID: 20215785.
A. Lorch, C. Bascoul-Mollevi, A. Kramar, L. Einhorn i inni. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. „J Clin Oncol”. 29 (16), s. 2178–2184, 2011. DOI: 10.1200/JCO.2010.32.6678. PMID: 21444870.
J. Beyer, S. Stenning, A. Gerl, S. Fossa i inni. High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis. „Ann Oncol”. 13 (4), s. 599–605, 2002. PMID: 12056711.
K. Oechsle, C. Kollmannsberger, F. Honecker, F. Mayer i inni. Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors. „Eur Urol”. 60 (4), s. 850–855, 2011. DOI: 10.1016/j.eururo.2011.06.019. PMID: 21704446.
N. Nicolai, A. Necchi, L. Gianni, L. Piva i inni. Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours. „BJU Int”. 104 (3), s. 340–346, 2009. DOI: 10.1111/j.1464-410X.2009.08453.x. PMID: 19239440.
W. Sui, D.C. Morrow, C.E. Bermejo, N.J. Hellenthal. Trends in Testicular Cancer Survival: A Large Population-based Analysis. „Urology”. 85 (6), s. 1394–1398, 2015. DOI: 10.1016/j.urology.2015.03.022. PMID: 26099885.
R.H. Verhoeven, A. Gondos, M.L. Janssen-Heijnen, K.U. Saum i inni. Testicular cancer in Europe and the USA: survival still rising among older patients. „Ann Oncol”. 24 (2), s. 508–513, 2013. DOI: 10.1093/annonc/mds460. PMID: 23110807.
N. Hanna, L.H. Einhorn. Testicular cancer: a reflection on 50 years of discovery. „J Clin Oncol”. 32 (28), s. 3085–3092, 2014. DOI: 10.1200/JCO.2014.56.0896. PMID: 25024068.
M.C. LI, R. Hertz, D.M. Bergenstal. Therapy of choriocarcinoma and related trophoblastic tumors with folic acid and purine antagonists. „N Engl J Med”. 259 (2), s. 66–74, 1958. DOI: 10.1056/NEJM195807102590204. PMID: 13566422.
R.H. Blum, S.K. Carter, K. Agre. A clinical review of bleomycin--a new antineoplastic agent. „Cancer”. 31 (4), s. 903–914, 1973. PMID: 4122362.
M.L. Samuels, C.D. Howe. Vinblastine in the management of testicular cancer. „Cancer”. 25 (5), s. 1009–1017, 1970. PMID: 5443728.
M.L. Samuels, D.E. Johnson, P.Y. Holoye. Continuous intravenous bleomycin (NSC-125066) therapy with vinblastine (NSC-49842) in stage III testicular neoplasia. „Cancer Chemother Rep”. 59 (3). s. 563–570. PMID: 54212.
D.J. Higby, H.J. Wallace, D.J. Albert, J.F. Holland. Diaminodichloroplatinum: a phase I study showing responses in testicular and other tumors. „Cancer”. 33 (5), s. 1219–1215, 1974. PMID: 4856724.
L.H. Einhorn, J. Donohue. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. „Ann Intern Med”. 87 (3), s. 293–298, 1977. PMID: 71004.
J.D. Hainsworth, S.D. Williams, L.H. Einhorn, R. Birch i inni. Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin: results of a Southeastern Cancer Study Group trial. „J Clin Oncol”. 3 (5), s. 666–671, 1985. DOI: 10.1200/JCO.1985.3.5.666. PMID: 2582097.
G.J. Bosl, R. Gluckman, N.L. Geller, R.B. Golbey i inni. VAB-6: an effective chemotherapy regimen for patients with germ-cell tumors. „J Clin Oncol”. 4 (10), s. 1493–1499, 1986. DOI: 10.1200/JCO.1986.4.10.1493. PMID: 2428948.
G.J. Bosl, N.L. Geller, D. Bajorin, S.P. Leitner i inni. A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. „J Clin Oncol”. 6 (8), s. 1231–1238, 1988. DOI: 10.1200/JCO.1988.6.8.1231. PMID: 2457657.
S.D. Williams, R. Birch, L.H. Einhorn, L. Irwin i inni. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. „N Engl J Med”. 316 (23), s. 1435–1440, 1987. DOI: 10.1056/NEJM198706043162302. PMID: 2437455.
onkologia.org.pl
Krajowy Rejestr Nowotworów: Jądro. [dostęp 2018-04-03]. [zarchiwizowane z tego adresu].
